About: New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets
Creator	Osterhaus, Albert Goudsmit, Jaap Kompier, Ronald Koudstaal, Wouter Brakenhoff, Just Friesen, Robert Koldijk, Martin Lenting, Peter Stittelaar, Koert Weverling, Gerrit
Source	Medline; PMC
abstract	BACKGROUND: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic. A recently discovered class of human monoclonal antibodies with the ability to neutralize a broad spectrum of influenza viruses (including H1, H2, H5, H6 and H9 subtypes) has the potential to prevent and treat influenza in humans. Here we report the latest efficacy data for a representative antibody of this novel class. METHODOLOGY/PRINCIPAL FINDINGS: We evaluated the prophylactic and therapeutic efficacy of the human monoclonal antibody CR6261 against lethal challenge with the highly pathogenic avian H5N1 virus in ferrets, the optimal model of human influenza infection. Survival rates, clinically relevant disease signs such as changes in body weight and temperature, virus replication in lungs and upper respiratory tract, as well as macro- and microscopic pathology were investigated. Prophylactic administration of 30 and 10 mg/kg CR6261 prior to viral challenge completely prevented mortality, weight loss and reduced the amount of infectious virus in the lungs by more than 99.9%, abolished shedding of virus in pharyngeal secretions and largely prevented H5N1-induced lung pathology. When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage. CONCLUSIONS/SIGNIFICANCE: These data demonstrate the prophylactic and therapeutic efficacy of this new class of human monoclonal antibodies in a highly stringent and clinically relevant animal model of influenza and justify clinical development of this approach as intervention for both seasonal and pandemic influenza.
has issue date	2010-02-08(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0009106
bibo:pmid	20161706
has license	cc-by
sha1sum (hex)	10abe76a05511196ea1f252383f0c70d592e7444
schema:url	https://doi.org/10.1371/journal.pone.0009106
resource representing a document's title	New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets
has PubMed Central identifier	PMC2817000
has PubMed identifier	20161706
schema:publication	PLoS One
resource representing a document's body	covid:10abe76a05511196ea1f252383f0c70d592e7444#body_text
is schema:about of	named entity 'INFLUENZA' named entity 'influenza' named entity 'PROPHYLACTIC' named entity 'SEVERE' covid:arg/10abe76a05511196ea1f252383f0c70d592e7444 named entity 'MONOCLONAL ANTIBODIES' named entity 'RESISTANCE' named entity 'H5N1' named entity 'H1N1' named entity 'H1N1 INFLUENZA' named entity 'ANTIVIRAL DRUG' named entity 'TREAT' named entity 'SUBTYPE' named entity 'HIGHLY' named entity 'OCCURRENCES' named entity 'URGENT' named entity 'BROAD SPECTRUM' named entity 'HUMANS' named entity 'BACKGROUND' named entity 'OSELTAMIVIR' named entity 'SWINE' named entity 'INFLUENZA PANDEMIC' named entity 'NOVEL' named entity 'INFLUENZA VIRUSES' named entity 'WIDESPREAD' named entity 'CLASS' named entity 'INFECTIONS' named entity 'NEED FOR' named entity 'INFLUENZA' named entity 'PANDEMIC' named entity 'REPORT' named entity 'HERE' named entity 'THERAPEUTIC EFFICACY' named entity 'CIRCULATING' named entity 'APPROACHES' named entity 'FERRETS' named entity 'HUMAN' named entity 'PATHOGENIC' named entity 'THREAT' named entity 'TO CONTROL' named entity 'CLASS' named entity 'DATA' named entity 'ORIGIN' named entity 'TO PREVENT' named entity 'ANTIBODY' named entity 'LATEST' named entity 'RECENTLY' named entity 'NEW' named entity 'MONOCLONAL ANTIBODIES' named entity 'MEDICAL' named entity 'LEADING' named entity 'REPRESENTATIVE' named entity 'EVOLVING' named entity 'EFFICACY' named entity 'VIRUSES' named entity 'POTENTIAL' named entity 'AVIAN' named entity 'prevent' named entity 'human' named entity 'representative' named entity 'discovered' named entity 'influenza pandemic' named entity 'avian' named entity 'monoclonal antibodies' named entity 'posed' named entity 'viruses' named entity 'broad spectrum' named entity 'antiviral drug' named entity 'swine-origin H1N1 influenza' named entity 'antibody' named entity 'influenza' named entity 'antibodies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software